• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


Evolut R and PRO Sys Registry-Based Low Risk RWU

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Study Pending
Application Number P130021 S058/ PAS002
Study Name Evolut R and PRO Sys Registry-Based Low Risk RWU
General Study Protocol Parameters
Study Design Comprehensive/Linked/RegistryBased Surveillance
Data Source External Registry
Comparison Group Historical Control
Analysis Type Descriptive
Study Population Adult: >21

Evolut R and PRO Sys Registry-Based Low Risk RWU Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
one year report 01/15/2020    
two year report 01/15/2021    
three year report 01/15/2022    
four year report 01/15/2023    
five year report 01/15/2024    
six year report 01/15/2025    
seven year report 01/15/2026    
eight year report 01/15/2027    
nine year report 01/15/2028    
ten year report 01/15/2029    

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Related Links